Companies: 10,795·Total market cap: $144.5T
Crescita Therapeutics Inc.

Crescita Therapeutics Inc.

CTX.TOTSXHealthcare● Active
$0.79
+$0.00(+0.00%)
Market Cap$14705011
P/E Ratio—
52W High$0.79
52W Low$0.4
Free Cash FlowFinancialsRevenue

Crescita Therapeutics Inc. (CTX.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CTX.TO · free cash flow · updated Jun 8, 2026

Core FCF metrics

Free cash flow was $740,000 for FY2025 (fiscal year ending 2025-12-31), down 51.9% year-over-year The FCF margin was 3.5%. Five-year CAGR stands at -33.2%.

FY2025 Free Cash Flow$740,000▼ -51.9% YoY
Trailing 12M (TTM)$2.2Mtrailing 4 quarters sum
FCF Margin3.5%$740,000 ÷ revenue
3-Year CAGRN/AN/A — contains negative FCF
5-Year CAGR-33.2%FY2020 → FY2025
FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0
Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

Positive FCFNegative FCF
Free Cash Flow
YoY Growth %
ctx.to free cash flow history · ctx.to free cash flow chart · ctx.to free cash flow growth rate · ctx.to free cash flow last 10 years

Annual free cash flow data

Fiscal YearFree Cash FlowYoY ChangeFCF Margin
FY2025Latest$740,000▼ 51.9%3.5%
FY2024$1.5M▼ 20.7%7.9%
FY2023$1.9M▲ +255.6%11.1%
FY2022−$1.2M▲ +35.7%-5.3%
FY2021−$1.9M▼ 135.0%-11.6%
FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP
ctx.to free cash flow 2025 · ctx.to free cash flow 2024 · ctx.to free cash flow 2023 · ctx.to operating cash flow

FCF valuation metrics

Crescita Therapeutics Inc. (CTX.TO) trades at a FCF yield of 15.08% and a price-to-free-cash-flow ratio of 6.6x. FCF per share stands at $0.12, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)
15.08%
Free Cash Flow ÷ Market Cap
per FMP freeCashFlowYieldTTM definition
FCF per Share (TTM)
$0.12
TTM FCF ÷ Shares Outstanding
Price / FCF
x6.6
Share Price ÷ FCF per Share
EV / FCF (TTM)
x3.8
Enterprise Value basis
Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31
ctx.to price to free cash flow · ctx.to free cash flow yield · ctx.to free cash flow per share · ctx.to price to cash flow ratio

Cash flow statement summary

For FY2025, Crescita Therapeutics Inc. generated $1.1M in operating cash flow and spent 0M in capital expenditures, yielding $0.7M in free cash flow.

Operating Activities
+$1.1M
Cash from core business operations
2025-12-31
Investing Activities
−$1.0M
CapEx, acquisitions & investments
2025-12-31
Financing Activities
−$0.8M
Buybacks, dividends & debt
2025-12-31
FCF FormulaOperating CF ($1.1M) − |CapEx| (0M) = FCF ($0.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →
ctx.to cash flow statement · ctx.to cash flow statement 2025 · ctx.to operating cash flow · ctx.to cash flow from operations

Free cash flow vs peers (Healthcare)

#CompanyFree Cash FlowYoY
#1
Crescita Therapeutics Inc.
Crescita Therapeutics Inc.YOU
CTX.TO
$740,000-51.9%
#2
Johnson & Johnson
Johnson & Johnson
JNJ
$19.70B-0.7%#3
AbbVie Inc.
AbbVie Inc.
ABBV
$17.82B-0.1%#4
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$16.07B-22.4%#5
Eli Lilly and Company
Eli Lilly and Company
LLY
$8.97B+2065.6%
Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Crescita Therapeutics Inc. (CTX.TO) reported free cash flow of $740,000 for FY2025 (fiscal year ending 2025-12-31), down 51.9% year-over-year. The FCF margin was 3.5%.

Based on available data, Crescita Therapeutics Inc. has maintained positive free cash flow for at least 5 fiscal year(s). FCF peaked at $5.5M in FY2020. The 5-year CAGR stands at -33.2%.

Crescita Therapeutics Inc.'s FCF yield is 15.08% and price-to-FCF ratio is 6.6x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.
RevenueFinancial statementsNet incomeEarningsForecastPrice historyMarket capCash on handP/E ratio

Frequently asked questions

CTX.TO free cash flow · 8 questions

Crescita Therapeutics Inc. free cash flow was $740,000 for FY2025, down 51.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $2.2M.

CTX.TO free cash flowCTX.TO FCFCTX.TO FCF 2025CTX.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Crescita Therapeutics Inc. · Crescita Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026